ARK Invest deployed over $10M in CRISPR Therapeutics and PayPay Corp on March 12, while cutting positions in Teradyne and Ionis Pharmaceuticals.

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.

Cathie Wood’s ARK ETF published their daily trades for Friday, March 13th, 2026, shedding light on significant movements in their investment strategy. The standout transaction of the day was the ...

Cathie Wood’s Ark Invest reshuffled positions across its ETFs during last week, adding positions to gene-editing and AI healthcare names while trimming genomics tools and semiconductor equipment ...

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

Cathie Wood has made a name for herself as an innovation-focused growth investor, and her leadership as the founder and CEO of Ark Invest has led some investors to pay close attention to the equity ...

In a smaller yet noteworthy trade, ARK purchased 25,000 shares of the 3iQ Solana Staking ETF (SOLQ), with a total value of $173,042. This acquisition reflects ARK’s interest in the growing ...

Cathie Wood’s ARK Invest made more than $10 million in trades on March 12, 2026, according to the firm’s daily disclosures.

This article looks at the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. ARK Investment Management LLC, or ARK ...

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.